.gif?ad=16248&adview=true)
![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Research Papers
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461.
Abstract
The myc family of cellular oncogenes encodes three highly related nuclear phosphoproteins (c-Myc, N-Myc, and L-Myc) that are believed to function as sequence-specific transcription factors capable of regulating genes important in cellular growth and differentiation. Current evidence indicates that Myc family proteins exist as biologically active heterodimeric complexes in association with another helix-loop-helix leucine zipper phosphoprotein, Max. We have investigated the common and unique properties among the Myc family, as well as the physiological role of Max in the regulation of Myc family function. We demonstrate that trans-activation-incompetent mutants of one Myc family member can act in trans to dominantly suppress the cotransformation activities of all three Myc oncoproteins, indicating that the Myc family functions through common genetic elements in its cellular transformation pathways. Employing co-immunoprecipitation with either anti-Myc or anti-Max antibodies, we show that the transfected normal c-Myc, N-Myc, and L-Myc oncoproteins associate with the endogenous Max protein in REF transformants, indicating that the Max interaction represents at least one component common to Myc family function. In addition, we observed a striking reduction in Myc cotransformation activity when a Max expression construct was added to myc/ras co-transfections. We discuss these biological findings in the context of a proposed model for Myc/Max function and regulation in which Max serves as either an obligate partner in the Myc/Max transcriptional complex or as a repressor in the form of a transcriptionally inert Max/Max homodimer capable of occupying Myc/Max-responsive gene targets.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Wlodarska, D. Dierickx, V. Vanhentenrijk, K. Van Roosbroeck, H. Pospisilova, F. Minnei, G. Verhoef, J. Thomas, P. Vandenberghe, and C. De Wolf-Peeters Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas Blood, June 15, 2008; 111(12): 5683 - 5690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. W. Yang, J. L. Kutok, N. H. Lee, H. Y. Piao, C. D. M. Fletcher, J. P. Kanki, and A. T. Look Targeted Expression of Human MYCN Selectively Causes Pancreatic Neuroendocrine Tumors in Transgenic Zebrafish Cancer Res., October 15, 2004; 64(20): 7256 - 7262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. He, Y.-Y. Cho, G. Liu, W.-Y. Ma, A. M. Bode, and Z. Dong p38 Mitogen-activated Protein Kinase Regulation of JB6 Cl41 Cell Transformation Promoted by Epidermal Growth Factor J. Biol. Chem., July 11, 2003; 278(29): 26435 - 26442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Billin, A. L. Eilers, K. L. Coulter, J. S. Logan, and D. E. Ayer MondoA, a Novel Basic Helix-Loop-Helix-Leucine Zipper Transcriptional Activator That Constitutes a Positive Branch of a Max-Like Network Mol. Cell. Biol., December 1, 2000; 20(23): 8845 - 8854. [Abstract] [Full Text]
|
|
|
|
|
|
G. Barrera-Hernandez, C. M. Cultraro, S. Pianetti, and S. Segal Mad1 Function Is Regulated through Elements within the Carboxy Terminus Mol. Cell. Biol., June 15, 2000; 20(12): 4253 - 4264. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. A. Malynn, I. M. de Alboran, R. C. O'Hagan, R. Bronson, L. Davidson, R. A. DePinho, and F. W. Alt N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation Genes & Dev., June 1, 2000; 14(11): 1390 - 1399. [Abstract] [Full Text]
|
|
|
|
|
|
A. N. Billin, A. L. Eilers, C. Queva, and D. E. Ayer Mlx, a Novel Max-like BHLHZip Protein That Interacts with the Max Network of Transcription Factors J. Biol. Chem., December 17, 1999; 274(51): 36344 - 36350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Facchini and L. Z. Penn The molecular role of Myc in growth and transformation: recent discoveries lead to new insights FASEB J, June 1, 1998; 12(9): 633 - 651. [Abstract] [Full Text]
|
|
|
|
|
|
M.-F. Bourgeade, A.-S. Defachelles, and Y. E. Cayre Myc Is Essential for Transformation by TEL/Platelet-Derived Growth Factor Receptor beta (PDGFRbeta ) Blood, May 1, 1998; 91(9): 3333 - 3339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Watanabe, Z.-Q. Pan, N. Schreiber-Agus, R. A. DePinho, J. Hurwitz, and Y. Xiong Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen PNAS, February 17, 1998; 95(4): 1392 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, S. Fan, and E. V. Prochownik Distinct Roles for MAX Protein Isoforms in Proliferation and Apoptosis J. Biol. Chem., July 11, 1997; 272(28): 17416 - 17424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Schreiber-Agus, D. Stein, K. Chen, J. S. Goltz, L. Stevens, and R. A. DePinho Drosophila Myc is oncogenic in mammalian cells and plays a role in the diminutive phenotype PNAS, February 18, 1997; 94(4): 1235 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E Ayer and R N Eisenman A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes & Dev., November 1, 1993; 7(11): 2110 - 2119. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Moens, B. Stanton, L. Parada, and J Rossant Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus Development, January 10, 1993; 119(2): 485 - 499. [Abstract] [PDF]
|
|
